Safety and Efficacy Study of FS 4 IU VH S/D (Fibrin Sealant With 4IU/mL Thrombin, Vapor Heated, Solvent/Detergent Treated) to Adhere Split Thickness Skin Grafts and Improve Wound Healing in Burn Patients

Baxter logo

Baxter

Status and phase

Completed
Phase 3

Conditions

Deep Partial or Full Thickness Wounds

Treatments

Biological: Fibrin Sealant, ARTISS 4IU/ml VH SD
Other: Staples

Study type

Interventional

Funder types

Industry

Identifiers

NCT00157131
550201

Details and patient eligibility

About

The primary objective of this study is to evaluate skin graft adherence and wound healing in burn patients to evaluate whether FS 4IU VH S/D is equivalent or superior to the current standard of care (staples). The primary endpoint is achievement of complete (100%) wound closure within 28 days.

Enrollment

150 patients

Sex

All

Ages

Under 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

* Subjects or their legal representatives, who have read, understood and signed a written informed consent. * Subjects of either sex. * Female subjects of childbearing potential with a negative urine or serum pregnancy test on admission. * Subjects who are \<= 65 years of age including pediatric subjects of all ages. * Subjects with total burn wounds measuring \<= 40% TBSA. * Subjects with a contiguous deep partial thickness/full thickness wound, between 2% and 8% TBSA or two comparable, bilateral wounds each measuring between 1% and 4% TBSA. * Wounds designated as test sites require autologous sheet skin grafts with a thickness of 8/1000" - 16/1000" * Subjects who are able, and willing to comply with the procedures required by the protocol.

Exclusion criteria

* Subjects with electrical burns. * Subjects with chemical burns * Digits and genitalia are excluded as test sites. * Subjects with infection at test area/test sites. * Subjects with test sites previously randomized and treated in this study. * Subjects with venous or arterial vascular disorder that directly affects a designated test area/test site. * Subjects with pre-existing hemolytic anemia * Subjects with diabetes mellitus. * Subjects with documented history of pathologically or pharmacologically induced immune deficiency. * Subjects judged to be chronically malnourished. * Subjects that are judged to have significant pulmonary compromise. * Subjects receiving systemic corticosteroids within 30 days prior to skin grafting (not including inhaled steroids). * Subjects with known or suspected hypersensitivity to bovine proteins. * Subjects participating in another clinical trial that is evaluating an unapproved drug or device.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

150 participants in 2 patient groups

FS 4IU VH S/D
Experimental group
Description:
FS 4IU VH S/D was administered intraoperatively to the wound bed by spray application using the TISSOMAT and Spray Set. Only the DUPLOJECTvii system and Spray Set (connection tube with sterile filter and spray head) device was used for simultaneous spray application of the study product. A thin layer of FS 4IU VH S/D was applied to the wound bed using a "painting motion" from side to side to achieve coverage. The recommended dosing volume was 2.0 to 4.0 mL/100 cm2. One 2-mL pack (4 mL total volume) of FS 4IU VH S/D applied using the TISSOMAT and Spray Set was sufficient to coat a wound bed of 100-200 cm2.
Treatment:
Biological: Fibrin Sealant, ARTISS 4IU/ml VH SD
Staples
Active Comparator group
Description:
Staples are the current standard of care in burn surgery and are well accepted as the control in this type of study.
Treatment:
Other: Staples

Trial contacts and locations

17

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems